We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+67.56%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$955M
AUM Growth
+$389M
Cap. Flow
+$199M
Cap. Flow %
20.8%
Top 10 Hldgs %
58.81%
Holding
63
New
12
Increased
9
Reduced
11
Closed
11

Top Buys

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$78.8M
2
APLS
Apellis Pharmaceuticals
APLS
+$55.5M
3
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$26.9M
4
BPMC
Blueprint Medicines
BPMC
+$26.4M
5
IFRX icon
InflaRx
IFRX
+$26M

Top Sells

Rank Stock Value
1
RXDX
Ignyta, Inc.
RXDX
+$43.2M
2
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$27M
3
OMER icon
Omeros
OMER
+$15.5M
4
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$11.9M
5
ALDR
Alder Biopharmaceuticals
ALDR
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 83.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANAB icon
1
AnaptysBio
ANAB
$1.54B
$126M 13.19%
1,251,485
+251,485
+25% +$18.5M
NKTR icon
2
Nektar Therapeutics
NKTR
$2.39B
$119M 12.49%
+133,180
New +$78.8M
APLS
3
DELISTED
Apellis Pharmaceuticals
APLS
$81.8M 8.56%
+3,768,757
New +$55.5M
NKTR icon
4
CALL
Nektar Therapeutics
NKTR
$2.39B
$44.8M 4.69%
+50,000
New +$29.6M
OMER icon
5
CALL
Omeros
OMER
$845M
$34M 3.56%
1,750,000
+1,000,000
+133% +$18.8M
BPMC
6
DELISTED
Blueprint Medicines
BPMC
$33.9M 3.55%
450,000
+375,000
+500% +$26.4M
MYOK
7
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$33.7M 3.53%
800,000
-271,889
-25% -$10.5M
DRNA
8
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$33M 3.46%
+3,656,669
New +$26.9M
IFRX icon
9
InflaRx
IFRX
$243M
$30.1M 3.15%
+1,438,207
New +$26M
JUNO
10
DELISTED
Juno Therapeutics, Inc.
JUNO
$25.1M 2.63%
550,000
+175,000
+47% +$8.73M
TBPH icon
11
Theravance Biopharma
TBPH
$873M
$25.1M 2.63%
900,000
-50,000
-5% -$1.48M
MRTX
12
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$22.5M 2.35%
1,231,522
+231,522
+23% +$3.59M
QTNT
13
DELISTED
Quotient Limited Ordinary Shares
QTNT
$22.2M 2.33%
112,203
+25,055
+29% +$4.82M
AVXS
14
DELISTED
AveXis, Inc. Common Stock
AVXS
$22.1M 2.32%
+200,000
New +$20.1M
KA
15
DELISTED
Kineta, Inc. Common Stock
KA
$19.2M 2.01%
23,571
-3,601
-13% -$1.38M
ARGX icon
16
argenx
ARGX
$55.2B
$18.3M 1.92%
+290,000
New +$9.5M
QTRX icon
17
Quanterix
QTRX
$159M
$18.2M 1.91%
+847,789
New +$16.5M
GTHX
18
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$17.8M 1.86%
897,505
– –
OMER icon
19
Omeros
OMER
$845M
$17M 1.78%
875,000
-825,000
-49% -$15.5M
NBIX icon
20
Neurocrine Biosciences
NBIX
$18.2B
$15.5M 1.62%
200,000
-50,000
-20% -$3.41M
BLUE
21
DELISTED
bluebird bio
BLUE
$14.2M 1.49%
6,176
-4,439
-42% -$9.01M
ANAB icon
22
CALL
AnaptysBio
ANAB
$1.54B
$13.6M 1.42%
+135,000
New +$9.94M
CLSD
23
DELISTED
Clearside Biomedical
CLSD
$13.6M 1.42%
129,392
– –
ACRS icon
24
Aclaris Therapeutics
ACRS
$715M
$13.6M 1.42%
550,000
– –
ASND icon
25
Ascendis Pharma A/S
ASND
$16.5B
$12M 1.26%
+300,000
New +$10.9M
1
2 3

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q4 2017 Portfolio in Review

As of Q4 2017, Cormorant Asset Management held 63 positions worth $955M, up 69% from $566M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Cormorant Asset Management deployed $199M of net new capital in Q4 2017, opening 12 new positions and adding to 9 existing holdings. Its largest new stake was Nektar Therapeutics: 133,180 shares worth $119M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 87% a quarter earlier.

On the sell side, the largest reduction was Omeros, an estimated $15.5M trimmed.

  • Cormorant Asset Management's largest Q4 2017 buy was Nektar Therapeutics: 133,180 shares worth $119M.
  • Cormorant Asset Management added most to Blueprint Medicines in Q4 2017, an estimated $26.4M increase.
  • Cormorant Asset Management's biggest Q4 2017 reduction was Omeros, cutting an estimated $15.5M.
  • Cormorant Asset Management fully exited Ignyta, Inc. in Q4 2017, selling an estimated $43.2M.
  • Cormorant Asset Management's ten largest holdings make up 59% of its $955M portfolio in Q4 2017.
  • Cormorant Asset Management opened 12 new positions and closed 11 in Q4 2017.
  • Cormorant Asset Management's portfolio value rose 69% quarter-over-quarter to $955M.

Based on Cormorant Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.